BioXcel Therapeutics, Inc.

BTAI · OTC

Share price · BTAI

$0.07-1.16 (-93.99%) 3M

no price since 4 Sep 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BTAI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Sep 2026-37.1%

    Nothing announced by BTAI that day or the session before.

  2. 28 Aug 2026-74.8%
  3. 17 Aug 2026-25.2%

    Nothing announced by BTAI that day or the session before.

  4. 12 Aug 2026+13.7%
  5. 14 Jul 2026+16.8%

    Nothing announced by BTAI that day or the session before.

  6. 8 Jul 2026-22.9%

    Nothing announced by BTAI that day or the session before.

  7. 6 Jul 2026-20.3%
  8. 30 Apr 2026+18.3%
  9. 1 Apr 2026-9.0%
  10. 17 Mar 2026+12.3%

    Nothing announced by BTAI that day or the session before.

Share of unusual movement by asset

For each asset, the share of BTAI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Dexmedetomidine (Igalmi) (Igalmi)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—86%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Alpha-2 adrenergic receptor (agonist)Small molecule
SchizophreniaBipolar DisorderAlzheimer's Disease
Alzheimer's Disease Agitation

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalDexmedetomidine (Igalmi)FDA approves IGALMI for at-home use
US, FDA · Source ↗
14 January 2026Filing submittedDexmedetomidine (Igalmi)sNDA submitted for at-home IGALMI
US, FDA · Source ↗
27 August 2025Topline resultDexmedetomidineSERENITY At-Home phase 3 safety topline
BioXcel Therapeutics · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.2M$3.2M$14M$15M-$6.1M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0.2M$3.0M$17M$13M-$12M operating cash flowreport ↗
2025-Q3$0.1M$8.7M$37M$31M-$19M operating cash flowreport ↗
2025-Q2$0.1M$10M$19M$19M-$13M operating cash flowreport ↗
2025-Q1$0.2M$4.5M$31M$7.3M-$12M operating cash flowreport ↗
2024-Q3$0.2M$5.1M$40M$14M-$16M operating cash flowreport ↗
2024-Q2$1.1M$8.0M$56M$8.3M-$23M operating cash flowreport ↗
2024-Q1$0.6M$11M$74M$27M-$18M operating cash flowreport ↗
2023-Q3$0.3M$20M$90M$50M-$38M operating cash flowreport ↗
2023-Q2$0.5M$27M$128M$54M-$38M operating cash flowreport ↗
2023-Q1$0.2M$28M$166M$53M-$52M operating cash flowreport ↗
2022-Q3$0.1M$22M$232M$42M-$31M operating cash flowreport ↗
2022-Q2—$18M$233M$38M-$33M operating cash flowreport ↗
2022-Q1—$19M$200M$31M-$32M operating cash flowreport ↗
2021-Q3—$12M$253M$27M-$20M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.6M$30M$29M$17M-$58M operating cash flowreport ↗

BioXcel Therapeutics reported full-year 2025 revenue of $0.64M, down 71.8% YoY, with R&D spend of $30.25M, down 0.6% YoY. Cash and equivalents totaled $28.76M, and the company reported a net loss of $69.9M.

During the period, the company submitted an sNDA to the FDA seeking approval of IGALMI in the at-home setting for acute agitation associated with bipolar disorders or schizophrenia, with potential approval as early as year-end 2026, and advanced commercial preparations based on a third-party market assessment. It also continued the TRANQUILITY In-Care Phase 3 program for agitation associated with Alzheimer’s dementia, receiving FDA feedback and selecting a CRO for trial initiation, and reported positive Phase 2 topline results from a Columbia University-led investigator-sponsored trial of BXCL501 for opioid withdrawal.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.3M$30M$30M$15M-$72M operating cash flowreport ↗
2023-FY$1.4M$84M$65M$45M-$155M operating cash flowreport ↗
2022-FY$0.4M$91M$194M$41M-$135M operating cash flowreport ↗
2021-FY—$53M$233M$27M-$82M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($43K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-12Atkins Susan E. · directorAward / grant (derivative)17,000——Form 4
2026-06-15Mehta Vimal · director, CEO and PresidentOption exercise219——Form 4
2026-06-15Yocca Frank · Chief Scientific OfficerOption exercise35——Form 4
2026-06-15Steinhart Richard I · Chief Financial OfficerOption exercise35——Form 4
2026-06-15Rodriguez Javier · See RemarksOption exercise35——Form 4
2026-06-15Mehta Vimal · director, CEO and PresidentOption exercise (derivative)219——Form 4
2026-06-15Yocca Frank · Chief Scientific OfficerOption exercise (derivative)35——Form 4
2026-06-15Steinhart Richard I · Chief Financial OfficerOption exercise (derivative)35——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 39 reporting institutions held 5.4M shares ($7.3M, 17.4% of shares outstanding).

#InstitutionSharesValue
1MILLENNIUM MANAGEMENT LLC1,936,760$2.6M
2ARMISTICE CAPITAL, LLC1,910,076$2.6M
3OAKTREE CAPITAL MANAGEMENT LP241,188$323K
4GEODE CAPITAL MANAGEMENT, LLC230,168$309K
5VANGUARD CAPITAL MANAGEMENT LLC207,339$278K
6JONES FINANCIAL COMPANIES LLLP131,789$166K
7Man Group plc96,473$129K
8STATE STREET CORP92,118$123K
9FMR LLC90,300$121K
10VANGUARD FIDUCIARY TRUST CO84,921$114K
11BlackRock, Inc.84,282$113K
12&PARTNERS80,864$108K
13UBS Group AG52,788$71K
14Oaktree Fund Advisors, LLC42,913$58K
15HighTower Advisors, LLC41,000$55K